- Home
- AIRT vs ACET Comparison
AIRT vs ACET Comparison
Compare AIRT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ACET
- Stock Information
- Founded
- AIRT 1980
- ACET 1947
- Country
- AIRT United States
- ACET United States
- Employees
- AIRT N/A
- ACET N/A
- Industry
- AIRT Air Freight/Delivery Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- ACET Health Care
- Exchange
- AIRT Nasdaq
- ACET Nasdaq
- Market Cap
- AIRT 59.6M
- ACET 60.5M
- IPO Year
- AIRT N/A
- ACET N/A
- Fundamental
- Price
- AIRT $25.42
- ACET $0.76
- Analyst Decision
- AIRT
- ACET Strong Buy
- Analyst Count
- AIRT 0
- ACET 7
- Target Price
- AIRT N/A
- ACET $5.60
- AVG Volume (30 Days)
- AIRT 1.5K
- ACET 608.9K
- Earning Date
- AIRT 08-13-2025
- ACET 11-05-2025
- Dividend Yield
- AIRT N/A
- ACET N/A
- EPS Growth
- AIRT N/A
- ACET N/A
- EPS
- AIRT N/A
- ACET N/A
- Revenue
- AIRT $296,309,000.00
- ACET N/A
- Revenue This Year
- AIRT N/A
- ACET N/A
- Revenue Next Year
- AIRT N/A
- ACET N/A
- P/E Ratio
- AIRT N/A
- ACET N/A
- Revenue Growth
- AIRT 5.14
- ACET N/A
- 52 Week Low
- AIRT $14.56
- ACET $0.45
- 52 Week High
- AIRT $26.70
- ACET $1.63
- Technical
- Relative Strength Index (RSI)
- AIRT 64.96
- ACET 57.42
- Support Level
- AIRT $22.63
- ACET $0.69
- Resistance Level
- AIRT $25.50
- ACET $0.75
- Average True Range (ATR)
- AIRT 0.46
- ACET 0.05
- MACD
- AIRT 0.21
- ACET 0.01
- Stochastic Oscillator
- AIRT 98.20
- ACET 89.93
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.